FILTER
FILTERED INTERVIEW RESULTS
Rodrigo Gutierrez
CEO, GTM HOLDINGS
GTM Holdings explains how it is experiencing increasing demand for chemicals across the spectrum in Latin America.
Etienne Lepoutre
PRESIDENT – LATIN AMERICA REGION, AIR LIQUIDE
Air Liquide explains how it is managing rapid demand for both industrial and medical gases in Latam.
Martin Sack
REGIONAL HEAD – AMERICAS, LESCHACO
Leschaco sees a buoyant market for the Latin American chemical trade, but major transport disruptions are a major issue.
Rina Quijada
VP BUSINESS DEVELOPMENT – RESEARCH LATIN AMERICA, IHS MARKIT
Rina Quijada discusses the main themes influencing Latin America’s petrochemical sector in 2021.
Ciro Marino
CEO, Brazilian Chemical Industry Association (ABIQUIM)
ABIQUIM discusses how Brazil’s chemical industry can become more competitive to supply increasing demand.
German Torres
CEO, BRENNTAG LATIN AMERICA
“The two challenges of digitalization are how to manage the substantial high number of transactions and how to manage the distribution channels. Having a nice website or platform is useless if you cannot deliver.”
Juan Moncada
MANAGING DIRECTOR LATIN AMERICA, EASTMAN
Eastman Latin America has maintained profitability during H1 2020 and continues introducing new sustainable products.
Ricardo Cuetos
VP AMERICAS STANDARD PRODUCTS, INEOS STYROLUTION
INEOS Styrolution explains the current market dynamics of the America’s and how it’s various units are coping.
Ciro Marino
CEO, ABIQUIM
Abiquim discusses the outlook for Brazil’s chemical industry and the implications of the government’s economic reforms, including the ‘New Gas Market’.
João Parolin
CEO, OXITENO
Oxiteno identifies good opportunities both at home in Brazil and elsewhere, despite the pandemic and Brazil’s faltering recovery.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
